BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cakir M, Dworakowska D, Grossman A. Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways. J Cell Mol Med 2010;14:2570-84. [PMID: 20629989 DOI: 10.1111/j.1582-4934.2010.01125.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, Spadazzi C, Miserocchi G, Recine F, Riva N, Nicolini S, Severi S, Martinelli G, Ibrahim T. Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers. Dis Markers 2018;2018:6878409. [PMID: 30627226 DOI: 10.1155/2018/6878409] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Garcia-Alvarez A, Hernando Cubero J, Capdevila J. Drug Development in Neuroendocrine Tumors: What Is on the Horizon? Curr Treat Options Oncol 2021;22:43. [PMID: 33786683 DOI: 10.1007/s11864-021-00834-3] [Reference Citation Analysis]
3 Zhao F, Zhou H, Li S, Fang Q, Luo Y, Hickford JGH. Growth and carcass trait association with variation in the somatostatin receptor 1 (SSTR1) gene in New Zealand Romney sheep. New Zealand Journal of Agricultural Research 2017;61:477-86. [DOI: 10.1080/00288233.2017.1415942] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
4 Kiesewetter B, Raderer M. My burning issues in neuroendocrine tumours (NET). Memo 2018;11:313-6. [PMID: 30595757 DOI: 10.1007/s12254-018-0449-2] [Reference Citation Analysis]
5 Zhao J, Chen Z, Kusnetzow AK, Nguyen J, Rico-Bautista E, Tan H, Betz SF, Struthers RS, Zhu Y. Discovery of substituted 3H-pyrido[2,3-d]pyrimidin-4-ones as potent, biased, and orally bioavailable sst2 agonist. Bioorg Med Chem Lett 2020;30:127496. [PMID: 32805408 DOI: 10.1016/j.bmcl.2020.127496] [Reference Citation Analysis]
6 Reubi JC, Schonbrunn A. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci 2013;34:676-88. [PMID: 24183675 DOI: 10.1016/j.tips.2013.10.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 7.6] [Reference Citation Analysis]
7 Stevenson M, Lines KE, Thakker RV. Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors: New Therapeutic Approaches. Endocrinol Metab Clin North Am 2018;47:525-48. [PMID: 30098714 DOI: 10.1016/j.ecl.2018.04.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
8 Frost M, Lines KE, Thakker RV. Current and emerging therapies for PNETs in patients with or without MEN1. Nat Rev Endocrinol 2018;14:216-27. [PMID: 29449689 DOI: 10.1038/nrendo.2018.3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
9 Olsen C, Memarzadeh K, Ulu A, Carr HS, Bean AJ, Frost JA. Regulation of Somatostatin Receptor 2 Trafficking by C-Tail Motifs and the Retromer. Endocrinology 2019;160:1031-43. [PMID: 30822353 DOI: 10.1210/en.2018-00865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kho M, Wang YZ, Chaar D, Zhao W, Ratliff SM, Mosley TH, Peyser PA, Kardia SLR, Smith JA. Accelerated DNA methylation age and medication use among African Americans. Aging (Albany NY) 2021;13:14604-29. [PMID: 34083497 DOI: 10.18632/aging.203115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Patel P, Galoian K. Molecular challenges of neuroendocrine tumors. Oncol Lett. 2018;15:2715-2725. [PMID: 29456718 DOI: 10.3892/ol.2017.7680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
12 Yu B, Zhang Z, Song H, Chi Y, Shi C, Xu M. Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma). Med Sci Monit 2017;23:1947-55. [PMID: 28434012 DOI: 10.12659/msm.903377] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
13 Herac M, Niederle B, Raderer M, Krebs M, Kaserer K, Koperek O. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis. APMIS 2016;124:839-45. [DOI: 10.1111/apm.12584] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
14 Gadelha MR, Kasuki L, Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends in Endocrinology & Metabolism 2013;24:238-46. [DOI: 10.1016/j.tem.2012.11.007] [Cited by in Crossref: 88] [Cited by in F6Publishing: 74] [Article Influence: 11.0] [Reference Citation Analysis]
15 Starr JS, Sonbol MB, Hobday TJ, Sharma A, Kendi AT, Halfdanarson TR. Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights. Onco Targets Ther. 2020;13:3545-3555. [PMID: 32431509 DOI: 10.2147/ott.s202867] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
16 Wang X, Luo D, Basilion JP. Photodynamic Therapy: Targeting Cancer Biomarkers for the Treatment of Cancers. Cancers (Basel) 2021;13:2992. [PMID: 34203805 DOI: 10.3390/cancers13122992] [Reference Citation Analysis]
17 Popa O, Taban SM, Pantea S, Plopeanu AD, Barna RA, Cornianu M, Pascu AA, Dema ALC. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. Exp Ther Med 2021;22:1179. [PMID: 34475969 DOI: 10.3892/etm.2021.10613] [Reference Citation Analysis]
18 Pavel M. Translation of molecular pathways into clinical trials of neuroendocrine tumors. Neuroendocrinology. 2013;97:99-112. [PMID: 22508344 DOI: 10.1159/000336089] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
19 Si Y, Kim S, Ou J, Lu Y, Ernst P, Chen K, Whitt J, Carter AM, Markert JM, Bibb JA, Chen H, Zhou L, Jaskula-Sztul R, Liu XM. Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy. Cancer Gene Ther 2021;28:799-812. [PMID: 32684623 DOI: 10.1038/s41417-020-0196-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
20 Walenkamp A, Crespo G, Fierro Maya F, Fossmark R, Igaz P, Rinke A, Tamagno G, Vitale G, Öberg K, Meyer T. Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment. Endocr Relat Cancer 2014;21:R445-60. [PMID: 25296914 DOI: 10.1530/ERC-14-0106] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
21 Fabian E, Haas B, Kump P, Lipp R, Kornprat P, Lutfi A, Talakic E, Fuchsjäger M, Spindelboeck W, Lackner C, Zollner G, Krejs GJ. Clinical-Pathological Conference Series from the Medical University of Graz : Case No 154: 32-year-old computer software engineer with nodular mass in the liver. Wien Klin Wochenschr 2016;128:277-86. [PMID: 26919853 DOI: 10.1007/s00508-016-0965-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Ibáñez-Costa A, Korbonits M. AIP and the somatostatin system in pituitary tumours. J Endocrinol 2017;235:R101-16. [PMID: 28835453 DOI: 10.1530/JOE-17-0254] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
23 Valiya Veettil M, Krishna G, Roy A, Ghosh A, Dutta D, Kumar B, Chakraborty S, Anju TR, Sharma-Walia N, Chandran B. Kaposi's Sarcoma-Associated Herpesvirus Infection Induces the Expression of Neuroendocrine Genes in Endothelial Cells. J Virol 2020;94:e01692-19. [PMID: 31969437 DOI: 10.1128/JVI.01692-19] [Reference Citation Analysis]
24 Kaltsas G, Grossman AB. The expanding role of somatostatin analogues in the treatment of neuroendocrine tumours: the CLARINET study. Clin Endocrinol (Oxf). 2015;83:759-761. [PMID: 26052840 DOI: 10.1111/cen.12831] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
25 Hormaechea‐agulla D, Jiménez‐vacas JM, Gómez‐gómez E, López FL, Carrasco‐valiente J, Valero‐rosa J, Moreno MM, Sánchez‐sánchez R, Ortega‐salas R, Gracia‐navarro F, Culler MD, Ibáñez‐costa A, Gahete MD, Requena MJ, Castaño JP, Luque RM. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. FASEB j 2017;31:4682-96. [DOI: 10.1096/fj.201601264rrr] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
26 Roohi S, Rizvi SK, Naqvi SAR. 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Indigenously Developed Freeze Dried Cold Kit and Biological Response in In-Vitro and In-Vivo Models. Dose Response 2021;19:1559325821990147. [PMID: 33628154 DOI: 10.1177/1559325821990147] [Reference Citation Analysis]
27 Kendler DB, Araújo Jr ML, Alencar R, de Souza Accioly MT, Bulzico DA, de Noronha Pessoa CC, Accioly FA, de Farias TP, Lopes FPPL, Corbo R, Vaisman M, Vaisman F. Somatostatin receptor subtype 1 might be a predictor of better response to therapy in medullary thyroid carcinoma. Endocrine 2017;58:474-80. [DOI: 10.1007/s12020-017-1424-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
28 Dworakowska D, Grossman AB. Aggressive and malignant pituitary tumours: state-of-the-art. Endocr Relat Cancer 2018;25:R559–R575. [PMID: 30306782 DOI: 10.1530/ERC-18-0228] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
29 Yue JT, Riddell MC, Burdett E, Coy DH, Efendic S, Vranic M. Amelioration of hypoglycemia via somatostatin receptor type 2 antagonism in recurrently hypoglycemic diabetic rats. Diabetes 2013;62:2215-22. [PMID: 23434929 DOI: 10.2337/db12-1523] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
30 Zhao J, Wang S, Han S, Kim SH, Kusnetzow AK, Nguyen J, Rico-Bautista E, Tan H, Betz SF, Scott Struthers R, Zhu Y. Discovery of nonpeptide 3,4-dihydroquinazoline-4-carboxamides as potent and selective sst2 agonists. Bioorg Med Chem Lett 2020;30:127391. [PMID: 32738999 DOI: 10.1016/j.bmcl.2020.127391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci 2019;20:E3049. [PMID: 31234481 DOI: 10.3390/ijms20123049] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 14.0] [Reference Citation Analysis]